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Summary
Background  and  purpose:  Although  serum  tenascin-C  (TN-C)  levels  are  related  to  left  ventricular
(LV) remodeling  in  patients  with  myocardial  infarction  and  are  useful  as  a  prognostic  biomarker
of heart  failure  in  patients  with  dilated  cardiomyopathy,  the  clinical  signiﬁcance  of  TN-C  levels
has not  yet  been  studied  in  patients  with  hypertrophic  cardiomyopathy  (HCM).  Therefore,  the
purpose of  this  study  is  to  elucidate  whether  serum  TN-C  levels  are  a  prognostic  biomarker  for
heart failure  in  patients  with  HCM.
Methods:  The  relationship  between  serum  TN-C  levels  and  heart  failure  events  was  studied  in
36 patients  with  HCM  during  follow-up.
Results:  Levels  of  serum  TN-C  were  28  ±  13  ng/ml  (range  11—80  ng/ml).  Although  patients  with
LV systolic  impairment  showed  higher  TN-C  levels  than  those  with  preserved  LV  systolic  function
(33 ±  11  ng/ml  vs.  27  ±  14  ng/ml;  p  =  0.16),  TN-C  levels  were  not  related  to  any  echocardio-
graphic parameters.  During  the  follow-up  period  of  4.8  ±  1.4  years,  heart  failure  events  were
observed in  six  patients  and  TN-C  levels  in  patients  with  events  were  higher  than  those  in
patients without  events.  Kaplan—Meier  analysis  showed  that  the  prognosis  was  worse  in  patients
with high  TN-C  levels  (≥39.2  ng/ml)  than  in  those  with  low  TN-C  levels.
Conclusions:  Heart  failure  events  were  more  frequently  observed  in  patients  with  high  serum
TN-C levels  than  in  those  with  low  TN-C  levels.  Serum  TN-C  levels  may  be  a  new  prognostic
biomarker for  heart  failure  in  patients  with  HCM.
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ypertrophic  cardiomyopathy  (HCM)  is  a  primary  myocardial
isease  that  has  been  deﬁned  as  a  left  ventricular  (LV)  hyper-
rophy  mainly  caused  by  mutations  in  one  of  the  12  genes
ncoding  proteins  of  the  cardiac  sarcomere  [1,2]. Although
he  natural  history  of  HCM  varies  from  an  asymptomatic
nd  benign  clinical  course  to  sudden  premature  death,  a
igniﬁcant  part  of  patients  with  HCM  suffers  from  heart
ailure  symptoms  due  to  LV  diastolic  and/or  systolic  dys-
unction  following  LV  remodeling  [3—5]. However,  clinical
nd  conventional  echocardiographic  examination  is  often
nable  to  predict  the  occurrence  of  heart  failure  events
n  patients  with  HCM  because  of  a  variety  of  underlying
auses.
The  efﬁcacy  of  biomarkers,  particularly  B-type  natri-
retic  peptide  (BNP),  in  predicting  heart  failure  events  has
een  conﬁrmed  in  patients  with  myocardial  infarction  or
ilated  cardiomyopathy  [6,7]. However,  the  clinical  utility
f  BNP  in  patients  with  HCM  is  controversial  [8—10]. There-
ore,  a  new  biomarker  is  needed  to  predict  heart  failure
vents  in  patients  with  HCM  [11]. Tenascin-C  (TN-C)  is  an
xtracellular  matrix  glycoprotein  expressed  during  embryo-
enesis,  and  it  is  re-expressed  under  pathologic  conditions
uch  as  myocardial  infarction  and  dilated  cardiomyopathy
12].  Clinically,  serum  TN-C  levels  are  associated  with  LV
emodeling  in  patients  with  acute  myocardial  infarction
13,14].  Moreover,  it  was  recently  reported  that  TN-C  levels
ere  useful  for  prognosis  of  heart  failure  in  patients  with
ilated  cardiomyopathy  [15]. Although  serum  TN-C  levels
re  also  elevated  in  patients  with  LV  hypertrophy  [16], the
linical  signiﬁcance  of  serological  TN-C  levels  has  not  yet
een  studied  in  patients  with  HCM.  Therefore,  the  purpose
f  this  study  was  to  elucidate  whether  serum  TN-C  lev-
ls  are  useful  in  predicting  heart  failure  events  in  patients
ith  HCM.
ethods
atients  and  study  design
hirty-six  patients  with  HCM  were  enrolled  in  this  ret-
ospective  study.  The  diagnosis  of  HCM  was  based  on
chocardiographic  demonstrations  of  a  hypertrophied,
ondilated  left  ventricle  (maximum  wall  thickness  ≥15  mm)
n  the  absence  of  systemic  hypertension  or  other  cardiac
isease  (e.g.  aortic  stenosis)  capable  of  producing  clini-
ally  evident  hypertrophy  at  some  point  of  clinical  course
1,2].  Patients  with  lung  disease,  liver  disease,  malig-
ancy,  collagen  disease,  renal  dysfunction  (creatinine  levels
2.0  mg/dl),  and  evident  coronary  artery  disease  were
xcluded  from  this  study.
The  clinical  and  laboratory  parameters  as  well  as
chocardiographic  characteristics  of  the  patients  were
etermined  when  they  were  clinically  stable  at  baseline.
he  beginning  of  follow-up  was  deﬁned  as  the  day  of  blood
ampling.  They  were  monitored  in  our  hospital,  and  the
ccurrence  of  heart  failure  was  observed.  Heart  failure
vents  were  deﬁned  as  worsening  dyspnea  within  the  con-
ext  of  pulmonary  congestion  on  chest  X-ray.
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The  Ethics  Committee  for  Medical  Research  at  our  institu-
ion  approved  the  study  protocol,  and  all  patients  provided
ritten  informed  consent  to  participate.
chocardiography
chocardiographic  images  were  acquired  using  a  digital
ltrasound  system  (Sequoia  512;  Acuson,  Mountain  View,  CA,
SA).  The  dimensions  of  the  left  ventricle  and  atrium  were
easured,  and  the  magnitude  and  distribution  of  LV  hyper-
rophy  were  assessed  from  the  two-dimensional  images.  The
aximum  wall  thickness  measured  at  any  site  in  the  left  ven-
ricle  was  regarded  as  the  maximal  thickness  as  previously
escribed  [10]. The  intraventricular  pressure  gradient  was
lso  measured  under  basal  conditions  using  continuous-wave
oppler,  and  LV  outﬂow  tract  gradient  of  ≥30  mmHg  was  con-
idered  signiﬁcant.  LV  systolic  impairment  was  deﬁned  as  LV
jection  fraction  ≤50%.
iomarkers  measurements
eripheral  venous  blood  samples  were  collected  during  clin-
cally  stable  periods  from  the  antecubital  veins  of  patients
fter  they  had  been  supine  for  15  min  without  drug  discontin-
ation.  Serum  was  separated  by  centrifugation  at  3500  × g
or  15  min.  Aliquots  were  stored  at  −80 ◦C.  We  measured
erum  TN-C  levels  with  the  large  subunit  containing  the  C
ominant  of  FN  III  repeats  level  using  one-step  sandwich
nzyme  immunoassay  kits  (Immuno-Biological  Laboratories
o.,  Ltd.  Takasaki,  Japan)  [17]. In  addition,  plasma  BNP
evel  was  measured  using  an  enzyme  immunoassay  (Tosoh
I;  Tosoh,  Tokyo,  Japan).
Estimated  glomerular  ﬁltration  rate  (GFR)  was  cal-
ulated:  estimated  GFR  =  194  × age−0.287 × serum  creati-
ine  level−1.094 in  men,  194  ×  age−0.287 ×  serum  creatinine
evel−1.094 ×  0.739  in  women.
tatistical  methods
ata  are  expressed  as  mean  ±  SD.  Two  groups  were  com-
ared  using  the  Wilcoxon  test.  Correlations  between  2
ontinuous  variables  were  evaluated  using  linear  regression
nalysis.  Noncontinuous  variables  expressed  as  proportions
ere  compared  using  the  2 test  or  the  Fisher  exact  test.
eceiver  operating  characteristic  curves  were  analyzed  to
etermine  the  prognostic  ability  of  TN-C.  Cutoff  point
eﬁned  as  the  points  on  the  curves  with  maximum  sensi-
ivity  and  speciﬁcity  was  used  for  Kaplan—Meier  estimates
f  event-free  survival.  The  statistical  difference  between
he  Kaplan—Meier  estimates  was  assessed  using  the  log-rank
est.  p-Values  of  <0.05  were  considered  signiﬁcant.  Data
ere  statistically  analyzed  using  the  JMP  version  8.0  soft-
are  (SAS  Institute  Inc.,  Cary,  NC,  USA).
esultsasic  characteristics  of  all  patients  are  shown  in  Table  1.
ost  patients  had  no  or  mild  symptoms.  Signiﬁcant  LV
utﬂow  gradient  at  rest  was  observed  in  three  patients.
V  outﬂow  gradient  was  more  than  50  mmHg  in  all  three
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Table  1  Patients’  characteristics  with  echocardiographic  and  laboratory  ﬁndings.
Variables  All  patients  Events  (+)  Events  (−)  p-Value
N  36  6  30
Age (years)  55  ±  14  66  ±  16  53  ±  13  0.1
Male, n  (%)  21  (58)  4  (67)  17  (57)  0.65
NYHA class  I/II,  n  (%)  31  (86)  3  (50)  28  (93)  0.005
Familial HCM,  n  (%)  14  (38)  4  (67)  18  (60)  0.76
Atrial ﬁbrillation,  n  (%) 8  (22)  5  (83)  3  (10)  <  0.0001
Medication
Beta blocker,  n  (%) 22 (62)  4 (67)  18  (60)  0.76
Calcium channel  blocker,  n  (%) 7 (19)  3 (50)  4 (13)  0.07
ACE inhibitor/ARB,  n  (%) 10 (28)  5 (83)  5 (17)  0.004
Amiodarone,  n  (%)  4  (11)  3  (50)  1  (3)  0.01
Estimated GFR  (ml/min/1.73  m2)  74.5  ±  17.2  66.7  ±  13.5  76.1  ±  17.7  0.20
Plasma BNP  levels  (pg/ml) 259  ±  191  340  ±  198  243  ±  189  0.29
Echocardiographic  ﬁndings
LV  end-diastolic  dimension  (mm)  44.8  ±  7.7  53.8  ±  5.9  43.0  ±  6.7  0.004
LV end-systolic  dimension  (mm)  28.1  ±  9.2  39.5  ±  8.3  25.8  ±  7.6  0.002
Intraventricular  septal  thickness  (mm)  18.3  ±  4.9  13.8  ±  3.9  19.2  ±  4.6  0.01
Posterior wall  thickness  (mm)  10.9  ±  2.7  10.0  ±  1.3  11.0  ±  2.9  0.48
Maximum LV  wall  thickness  (mm)  21.1  ±  4.8  16.8  ±  3.2  22.0  ±  4.7  0.02
Left atrial  dimension  (mm)  44.5  ±  7.5  54.58  ±  7.3  42.5  ±  5.9  0.002
Fractional shortening  (%)  38.6  ±  10.2  27.2  ±  9.6  40.9  ±  8.8  0.004
E wave  (mm)  75.9  ±  30.1  79.3  ±  11.9  75.2  ±  33.5  0.23
Deceleration  time  (ms)  226.8  ±  70  180.7  ±  43.0  236  ±  71  0.05
LV systolic  impairment,  n  (%)  6  (17)  4  (67)  2  (7)  0.003
LV outﬂow  tract  gradient,  n  (%)  3  (17)  0  (0)  3  (8)  0.4
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operating  characteristic  curve  of  TN-C  level  to  predict  heart
failure  was  39.2  ng/ml  (Fig.  2).  Patients  were  divided  into
two  groups  according  to  their  TN-C  levels.  No  statistical
difference  was  observed  in  the  clinical  (except  medication)ACE, angiotensin-converting enzyme; ARB, angiotensin receptor bl
HCM, hypertrophic cardiomyopathy; LV, left ventricular; NYHA, Ne
patients  (mean  90  ±  34  mmHg).  Six  patients  (17%)  showed  LV
systolic  impairment,  whereas  none  of  the  patients  showed
the  phenotype  of  apical  HCM.
During  the  follow-up  period  of  4.8  ±  1.4  years,  heart
failure  events  were  observed  in  six  patients  (17%).  The  com-
parison  between  patients  with  events  and  those  without
events  is  also  shown  in  Table  1.  Among  the  six  patients
with  heart  failure  events,  the  echocardiographic  phenotype
was  LV  systolic  impairment  in  four  (67%)  and  nonobstruc-
tion  with  preserved  LV  systolic  function  was  observed  in  two
patients  (33%).  None  of  obstructive  HCM  reached  end-point.
Consequently,  patients  with  events  had  severe  symptoms,
higher  prevalence  of  atrial  ﬁbrillation,  higher  prevalence  of
angiotensin-converting  enzyme  inhibitor/angiotensin  recep-
tor  blocker  and  amiodarone,  larger  LV  and  left  atrial
dimensions,  and  deteriorated  LV  systolic  function  compared
with  patients  without  events.
TN-C  levels  and  heart  failure  events
Levels  of  serum  TN-C  and  plasma  BNP  were  28  ±  13  ng/ml
(range  11—80  ng/ml)  and  259  ±  191  pg/ml  (range
15—696  pg/ml),  respectively.  Although  serum  TN-C  lev-
els  in  patients  with  LV  systolic  impairment  were  higher
than  that  in  patients  with  preserved  systolic  function
(33  ±  11  ng/ml  vs.  27  ±  14  ng/ml;  p  =  0.16),  serum  TN-C
levels  were  not  related  to  the  echocardiographic  data,
including  the  LV  dimension,  LV  systolic  function,  maximum
F
w; BNP, B-type natriuretic peptide; GFR, glomerular ﬁltration rate;
rk Heart Association.
V  wall  thickness,  and  left  atrial  dimension.  Moreover,
erum  TN-C  levels  in  patients  with  events  were  higher
han  those  in  patients  without  events  (Fig.  1).  On  the
ther  hand,  no  signiﬁcant  difference  in  plasma  BNP  levels
as  observed  between  patients  with  events  and  those
ithout  events  in  this  study  as  shown  in  Table  1.  Receiverigure  1  Comparison  of  tenascin-C  levels  between  patients
ith events  and  those  without  events.  TN,  tenascin.
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Table  2  Comparison  between  patients  with  high  and  low  TN-C  level.
Variables  High  TN-C  levels  Low  TN-C  levels  p-Value
N  6  30
Age (years)  62  ±  17  54  ±  12  0.18
Male, n  (%)  4  (67)  17  (57)  0.65
NYHA class  III/IV,  n  (%)  2  (33)  3  (10)  0.13
Familial HCM,  n  (%)  2  (33)  20  (67)  0.13
Atrial ﬁbrillation,  n  (%) 3  (50)  5  (17)  0.07
Medication
Beta blocker,  n  (%) 4 (67)  18 (60)  0.8
Calcium channel  blocker,  n  (%) 3 (50)  4 (13)  0.07
ACE inhibitor/ARB,  n  (%) 4 (67)  6 (20)  0.04
Amiodarone,  n  (%)  1  (4)  3  (10)  0.53
Estimated GFR  (ml/min/1.73  m2)  66.6  ±  17.4  76.1  ±  17.1  0.19
Plasma BNP  levels  (pg/ml) 266  ±  167  258  ±  198  0.8
Echocardiographic  ﬁndings
LV  end-diastolic  dimension  (mm)  45.7  ±  9.7  44.6  ±  7.5  0.91
LV end-systolic  dimension  (mm)  30.3  ±  12.3  27.7  ±  8.7  0.61
Intraventricular  septal  thickness  (mm)  16.8  ±  3.6  18.6  ±  5.1  0.34
Posterior wall  thickness  (mm)  9.5  ±  1.2  11.1  ±  2.8  0.1
Maximum LV  wall  thickness  (mm)  20.5  ±  5.3  21.3  ±  4.8  0.7
Left atrial  dimension  (mm)  48.8  ±  13  43.6  ±  5.9  0.55
Fractional shortening  (%)  35.7  ±  14,.5  39.2  ±  9.3  0.52
E wave  (mm)  75.5  ±  12.9  76  ±  33.5  0.49
Deceleration  time  (ms)  194.8  ±  54.8  233.2  ±  71.5  0.23
LV systolic  impairment,  n  (%)  2  (33)  4  (13)  0.23
LV outﬂow  tract  gradient,  n  (%)  0  (0)  3  (10)  0.41
ocker; BNP, B-type natriuretic peptide; GFR, glomerular ﬁltration rate;
w York Heart Association; TN-C, tenascin-C.
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nalysis  showed  that  prognosis  was  worse  in  patients  with
igh  TN-C  level  than  in  those  with  low  TN-C  level  (Fig.  3).
igure  2  Receiver  operating  characteristic  curves  to  predict
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Figure  3  Comparison  of  event-free  curves  between  patients
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iscussion
n  this  preliminary  study,  we  found  that  serum  TN-C  levels
ere  a  useful  prognostic  biomarker  for  heart  failure  in  36
atients  with  HCM.
Although  monitoring  and  preventing  sudden  death  is
mportant  in  patients  (particularly  in  young  patients)  with
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HCM,  a  signiﬁcant  part  of  patients  suffers  from  heart  failure-
related  symptoms  and  death  [18,19].  In  patients  with  HCM,
the  underlying  mechanism  of  heart  failure  is  responsible  for
(1)  evolution  into  LV  systolic  impairment  (end-stage  HCM
or  dilated  HCM),  (2)  obstruction  of  LV  outﬂow  tract,  and
(3)  nonobstruction  with  preserved  systolic  function  [18—23].
Melacini  and  colleagues  recently  reported  that  50  of  293
patients  (17%)  with  HCM  experienced  severe  heart  failure
during  a  follow-up  period  of  six  years,  and  the  incidence
of  end-stage  HCM,  LV  outﬂow  obstruction,  and  nonobstruc-
tion  with  preserved  systolic  function  was  30%,  22%,  and  48%,
respectively  [24]. Similarly,  six  of  the  36  patients  (17%)  suf-
fered  heart  failure  events  in  this  study.
Because  of  the  complex  mechanisms  of  heart  failure,  pre-
dicting  its  occurrence  in  patients  with  HCM  is  often  difﬁcult.
Although  conventional  Doppler  indices  driven  from  transmit-
tal  ﬂow  are  useful  in  patients  with  LV  systolic  dysfunction,
the  utility  is  limited  in  patients  with  HCM  [10]. Measurement
of  neurohormones  as  well  as  inﬂammatory  and  metabolic
biomarkers  can  help  us  understand  the  pathophysiology  of
cardiovascular  disease.  In  particular,  circulating  BNP  level
constitutes  an  established  prognostic  biomarker  in  patients
with  heart  failure  associated  with  myocardial  infarction
or  dilated  cardiomyopathy  [6,7]. However,  whether  plasma
BNP  level  is  useful  as  a  prognostic  biomarker  in  patients
with  HCM  continues  to  be  controversial  [8—10]. The  main
cause  of  discrepancy  is  the  complex  mechanism  of  BNP  reg-
ulation  in  patients  with  HCM,  i.e.  BNP  level  is  affected  by
several  factors  related  to  LV,  such  as  outﬂow  tract  gradient,
wall  thickness,  diastolic  dysfunction,  and  systolic  impair-
ment  [10,25].
TN-C  is  an  extracellular  matrix  protein  that  plays  an
important  role  in  the  development  of  the  myocardium,
valves,  and  coronary  vessels  during  embryonic  development
in  the  heart.  It  is  re-expressed  under  pathologic  condi-
tions  such  as  myocardial  infarction,  myocarditis,  and  dilated
cardiomyopathy,  and  it  is  related  to  the  process  of  LV  remod-
eling  [12]. Furthermore,  it  has  been  reported  that  serum
TN-C  levels  are  related  to  LV  remodeling  and  prognosis  in
patients  with  dilated  cardiomyopathy  and  myocardial  infarc-
tion  [13—15]. Moreover,  serum  TN-C  levels  are  elevated  in
patients  with  LV  hypertrophy  [16]. Therefore,  we  hypothe-
sized  that  TN-C  levels  may  help  in  the  prediction  of  heart
failure  events  in  patients  with  HCM.  Here,  serum  TN-C  lev-
els  in  patients  with  heart  failure  were  higher  than  those
in  patients  without  heart  failure  and  prognosis  was  worse
for  patients  with  high  TN-C  levels  than  for  those  with  low
TN-C  levels.  Interestingly,  TN-C  levels  were  not  related  to
any  echocardiographic  ﬁndings  or  plasma  BNP  levels,  in
contrast  to  the  previous  study  in  patients  with  dilated  car-
diomyopathy.  Although  it  is  interesting  whether  TN-C  levels
are  related  to  the  degree  of  LV  hypertrophy  or  LV  mass  in
patients  with  HCM,  we  could  not  evaluate  this  relationship
because  we  have  no  data  of  cardiac  magnetic  imaging  that
can  exactly  calculate  the  LV  mass  in  patients  with  asym-
metric  LV  hypertrophy.  Therefore,  the  precise  mechanism  of
regulation  of  TN-C  levels  and  the  relation  between  high  TN-
C  levels  and  heart  failure  in  patients  with  HCM  is  unclear  in
this  small  and  preliminary  study.  However,  this  study  may  be
able  to  explain  the  complex  mechanisms  of  heart  failure  in
patients  with  HCM.  Namely,  TN-C  levels  relate  to  LV  hyper-
trophy,  in  addition  to  LV  dilatation,  similar  to  the  relationre  events  in  patients  with  hypertrophic  cardiomyopathy213
etween  TN-C  and  LV  hypertrophy  in  hypertensive  patients
s  demonstrated  by  Franz  and  colleagues  [16]. Therefore,
N-C  levels  may  be  regulated  by  both  systolic  and  diastolic
unctions  in  patients  with  HCM.
imitations
everal  limitations  are  associated  with  this  study.  First,
he  study  population  was  small  with  a  retrospective  study
esign.  In  addition,  we  obtained  no  control  data.  Second,
he  levels  of  serological  biomarkers  were  measured  only
nce.  Third,  diastolic  function  assessed  by  tissue  Doppler
maging  is  focused  as  a  new  tool  for  prediction  of  progno-
is  [10], we  could  not  evaluate  the  tissue  Doppler  imaging
r  invasive  hemodynamic  parameters  because  of  the  study
esign.  The  cut-off  value  of  39.2  ng/ml  in  this  study  is
ower  compared  to  previous  reports  in  patients  with  dilated
ardiomyopathy  [15]. Although  the  precise  reason  of  this
ifference  is  unclear,  it  may  be  caused  by  disease  character-
stics.  In  addition,  multivariate  analysis  for  the  signiﬁcance
f  TN-C  was  not  performed  because  of  a  small  number  of
atients  and  prevalence  of  events.  Therefore,  the  precise
echanism  and  signiﬁcance  of  elevation  of  serum  TN-C  lev-
ls  in  patients  with  HCM  remains  unresolved  in  this  study.
n  additional  prospective  investigation  with  a  larger  patient
opulation  would  prove  useful  to  elucidate  the  signiﬁcance
f  TN-C  in  patients  with  HCM.
onclusion
n  patients  with  HCM,  the  prognosis  was  worse  for  patients
ith  high  TN-C  levels  than  for  those  with  low  TN-C  lev-
ls.  The  measurement  of  TN-C  levels  may  provide  a  new
rognostic  biomarker  for  heart  failure  in  patients  with  HCM.
eferences
[1] Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn
HJ, Seidman CE, Shah PM, Spencer 3rd WH, Spirito P, Ten
Cate FJ, Wigle ED. Task Force on Clinical Expert Consensus
Documents. American College of Cardiology; Committee for
Practice Guidelines. European Society of Cardiology. American
College of Cardiology/European Society of Cardiology Clinical
Expert Consensus Document on Hypertrophic Cardiomyopathy:
a report of the American College of Cardiology Foundation Task
Force on Clinical Expert Consensus Documents and the Euro-
pean Society of Cardiology Committee for Practice Guidelines.
J Am Coll Cardiol 2003;42:1687—713.
[2] Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Char-
ron P, Dubourg O, Kühl U, Maisch B, McKenna WJ, Monserrat L,
Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, et al. Classiﬁ-
cation of the cardiomyopahies: a position statement from the
European Society of Cardiology Working Group on Myocardial
and Pericardial Diseases. Eur Heart J 2008;29:270—6.
[3] Spirito P, Seidman CE, McKenna WJ, Maron BJ. The man-
agement of hypertrophic cardiomyopathy. N Engl J Med
1997;336:775—85.
[4] Maron BJ, Spirito P. Implications of left ventricular remod-
eling in hypertrophic cardiomyopathy. Am J Cardiol
1998;81:1339—44.
[5] Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS,
Udelson JE, Cecchi F, Maron BJ. Gender-related differences
2[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[14  
in the clinical presentation and outcome of hypertrophic car-
diomyopathy. J Am Coll Cardiol 2005;46:480—7.
[6] Tang WHW, Francis GS, Morrow DA, Newby LK, Cannon CP,
Jesse RL, Storrow AB, Christenson RH, Apple FS, Ravkilde
J, Wu AH. National Academy of Clinical Biochemistry Labo-
ratory Medicine, National Academy of Clinical Biochemistry
Laboratory Medicine practice guidelines: clinical utilization
of cardiac biomarker testing in heart failure. Circulation
2007;116:e99—109.
[7] Takahashi R, Negishi K, Watanabe A, Arai M, Naganuma
F, Ohyama Y, Kurabayashi M. Serum syndecan-4 is a novel
biomarker for patients with chronic heart failure. J Cardiol
2011;57:325—32.
[8] Maron BJ, Tholakanahalli VN, Zenovich AG, Casey SA, Duprez D,
Aeppli DM, Cohn JN. Usefulness of B-type natriuretic peptide
assay in the assessment of symptomatic state in hypertrophic
cardiomyopathy. Circulation 2004;109:984—9.
[9] Mutlu B, Bayrak F, Kahveci G, Fefertekin M, Eroglu E, Basaran
Y. Usefulness of N-terminal pro-B-type natriuretic peptide to
predict clinical course in patients with hypertrophic cardiomy-
opathy. Am J Cardiol 2006;98:1504—6.
10] Kitaoka H, Kubo T, Okawa M, Takenaka N, Sakamoto C, Baba Y,
Hayashi K, Yamasaki N, Matsumura Y, Doi YL. Tissue Doppler
imaging and plasma BNP levels to assess the prognosis in
patients with hypertrophic cardiomyopathy. J Am Soc Echo
2011;24:1020—5.
11] Kitaoka H, Kubo T, Okawa M, Takenaka N, Baba Y, Yamasaki
N, Matsumura Y, Furuno T, Doi YL. Plasma metalloproteinase
levels and left ventricular remodeling in hypertrophic car-
diomyopathy in patients with an identical mutation. J Cardiol
2011;58:261—5.
12] Imanaka-Yoshida K, Hiroe M, Yoshida T. Interaction between
cell and extracellular matrix in heart disease: multiple
roles of tenascin-C in tissue remodeling. Histol Histopathol
2004;19:517—25.
13] Sato S, Aonuma K, Imanaka-Yoshida K, Yoshida T, Isobe M,
Kawase D, Kinoshita N, Yazaki Y, Hiroe M. Serum tenascin-C
might be a novel predictor of left ventricular remodeling and
prognosis after acute myocardial infarction. J Am Coll Cardiol
2006;47:2319—25.
14] Terasaki F, Okamoto H, Onishi K, Sato A, Shimomura H, Tsukada
B, Imanaka-Yoshida K, Hiroe M, Yoshida T, Kitaura Y, Kitabatake
A. Study Group for Intractable Diseases by a Grant from the
Ministry of Health, Labor and Welfare of Japan. Higher serum
tenascin-C levels reﬂect the severity of heart failure, left ven-
tricular dysfunction and remodeling in patients with dilated
cardiomyopathy. Circ J 2007;71:327—30.H.  Kitaoka  et  al.
15] Fujimoto N, Onishi K, Sato A, Terasaki F, Tsukada B, Nozato T,
Yamada T, Imanaka-Yoshida K, Yoshida T, Ito M, Hiroe M. Incre-
mental prognostic values of serum tenascin-C levels with blood
B-type natriuretic peptide testing at discharge in patients with
dilated cardiomyopathy and decompensated heart failure. J
Card Fail 2009;15:898—905.
16] Franz M, Berndt A, Altendorf-Hofmann A, Fiedler N, Richter
P, Schumm J, Fritzenwanger M, Figulla HR, Brehm BR. Serum
levels of large tenascin-C variants, matrix metalloproteinase-9,
and tissue inhibitors of matrix metalloproteinases in concentric
versus eccentric left ventricular hypertrophy. Eur J Heart Fail
2009;11:1057—62.
17] Hasegawa M, Hirata H, Sudo A, Kato K, Kawase D, Kinoshita N,
Yoshida T, Uchida A. Tenascin-C concentration in synovial ﬂuid
correlates with radiographic progression of knee osteoarthritis.
J Rheumatol 2004;31:2021—6.
18] Maron BJ. Hypertrophic cardiomyopathy: a systematic review.
J Am Med Assoc 2002;287:1308—20.
19] Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE,
Graham KJ, Burton DA, Cecchi F. Epidemiology of hypertrophic
cardiomyopathy-related death. Circulation 2002;102:858—64.
20] Thaman R, Gimeno JR, Murphy RT, Kubo T, Sachdev B, Mogensen
J, Graham KJ, Burton DA, Cecchi F. Prevalence and clinical
signiﬁcance of systolic impairment in hypertrophic cardiomy-
opathy. Heart 2005;91:920—5.
21] Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F,
Lesser JR, Mackey-Bojack S, Manning WJ, Udelson JE, Maron BJ.
Prevalence, clinical proﬁle, and signiﬁcance of left ventricular
remodeling in the end-stage phase of hypertrophic cardiomy-
opathy. Circulation 2006;114:216—25.
22] Kitaoka H, Kubo T, Okawa M, Hitomi N, Furuno T, Doi YL.
Left ventricular remodeling of hypertrophic cardiomyopa-
thy: longitudinal observation in a rural community. Circ J
2006;70:1543—9.
23] Maron MS, Olivotto I, Betocchi S, Casey S, Lesser JR, Losi MA,
Cecchi F, Maron BJ. Effect of left ventricular outﬂow tract
obstruction in clinical outcome in hypertrophic cardiomyopa-
thy. N Engl J Med 2003;348:295—303.
24] Melacini P, Basso C, Angelini A, Calore C, Bobbo F, Tokajuk B,
Bellini N, Smaniotto G, Zucchetto M, Iliceto S, Thiene G, Maron
BJ. Clinicopathological proﬁles of progressive heart failure in
hypertrophic cardiomyopathy. Eur Heart J 2010;31:2111—23.
25] Briguori C, Betocchi S, Manganelli F, Gigante B, Losi MA,
Ciampi Q, Gottilla R, Violante A, Tocchetti CG, Volpe M,
Chiariello M. Determinants and clinical signiﬁcance of natri-
uretic peptides and hypertrophic cardiomyopathy. Eur Heart J
2001;22:1328—36.
